Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · December 07, 2022

ctDNA Mutation Tracking to Detect MRD and Trigger Intervention in Patients With Moderate- and High-Risk Early-Stage TNBC

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer
Ann. Oncol 2022 Nov 21;[EPub Ahead of Print], NC Turner, C Swift, B Jenkins, L Kilburn, M Coakley, M Beaney, L Fox, K Goddard, I Garcia-Murillas, P Proszek, P Hall, CH Wynne, T Hickish, S Kernaghan, IR Macpherson, A Okines, C Palmieri, S Perry, K Randle, C Snowdon, H Stobart, A Wardley, D Wheatley, S Waters, M Winter, M Hubank, S Allen, JM Bliss

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading